SCHEMBL2481240

SCHEMBL2481240

COc1ccc(CNc2cc(Cl)ncc2C(N)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
ASPH Q12797 2/20 0.56
KDM8 Q8N371 2/20 0.56
RIOX2 Q8IUF8 1/20 0.56
VNN1 O95497 4/20 0.53
CD38 P28907 1/20 0.53
AURKA O14965 5/20 0.51
RPS6KB1 P23443 5/20 0.51
JAK3 P52333 3/20 0.48
JAK2 O60674 2/20 0.48
IRAK4 Q9NWZ3 2/20 0.48
JAK1 P23458 1/20 0.48
TYK2 P29597 1/20 0.48
AURKB Q96GD4 2/20 0.47
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CCNA1 P78396 1/20 0.46
MAPK8 P45983 1/20 0.45
MAPK10 P53779 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29976764 0.90 KDM4E (0.56) KDM4EASPHKDM8RIOX2VNN1
SCHEMBL24157190 0.90 KDM4E (0.65) KDM4EASPHKDM8RIOX2VNN1
SCHEMBL30253210 0.90 KDM4E (0.65) KDM4EASPHKDM8RIOX2VNN1
SCHEMBL21723070 0.90 KDM4E (0.56) KDM4EASPHKDM8RIOX2VNN1
SCHEMBL2479534 0.87 AURKA (0.57) KDM4EVNN1AURKARPS6KB1JAK3
SCHEMBL15270392 0.86 GAA (0.56) KDM4EASPHKDM8RIOX2VNN1
SCHEMBL22749399 0.86 KDM4E (0.52) KDM4EASPHKDM8RIOX2VNN1
SCHEMBL31252847 0.86 GAA (0.56) KDM4EASPHKDM8RIOX2VNN1
SCHEMBL2479053 0.86 KDM4E (0.51) KDM4EVNN1CD38JAK3JAK2
SCHEMBL2479527 0.86 JAK3 (0.53) KDM4EVNN1CD38RPS6KB1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA KDM4E 1516/4885ASPH 4597/4885KDM8 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.